A Phase 2 12-Week Adaptive Open Label Sequential Cohort Trial to Evaluate the Efficacy Safety Tolerability and Pharmacokinetics of PF06730512 Following Multiple Doses in Adult Subjects with Focal Segmental Glomerulosclerosis (FSGS)

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.